Kornimate/medical-research-clean huggingface dataset:
heart failure and aortic stenosis transcriptome

Conditions: Heart Failure; Aortic Stenosis

Summary: this study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger rnas (mrnas), as well as long noncoding- (lncrnas) and micro noncoding-rnas (mirnas) in heart failure (hf) and in aortic stenosis (as). the aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. to this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.

the investigators will collect plasma and cardiac tissue specimens from consenting subjects. the investigators will evaluate the expression of mrnas, mirnas and lncrnas in patients affected by both end-stage and not end-stage hf as well as in patients affected by aortic stenosis and undergoing valve replacement and requiring cardiac myectomy. the tissue dysregulated rnas will be next measured in plasma samples in order to clarify their potential as biomarkers.

Eligibility criteria:
inclusion criteria: 1. non end-stage heart failure * left ventricle restoration surgery (svr) * end systolic volume index (esvi) \>35 ml/m2 * ejection fraction (ef)\<40% * previous transmural anterior myocardial infarction (mi) * age: 40-75 2. end-stage heart failure * left ventricle assisted device (lvad) surgery * age: 40-75 * ejection fraction (ef) \<25% * end systolic volume index (esvi)≥60 ml/m2 3. aortic stenosis * aortic valve replacement * intracardial pressure difference \>40 mmhg * septal diameter ≥1.3 cm exclusion criteria: 1. non end-stage heart failure * end systolic volume index (esvi)\<35 ml/m2 * ejection fraction (ef)\>40% * time from mi unknown * pregnancy * other genetic diseases * neoplasms * collagenopathies * chemo/radiotherapy * prolonged use of corticosteroids * infections * human immunodeficiency virus (hiv), hepatitis b virus (hbv) (not vaccination) and hepatitis c virus (hcv) positive 2. end-stage heart failure * ef\>25% * time from mi unknown * pregnancy * other genetic diseases * neoplasms * collagenopathies * chemo/radiotherapy * prolonged use of corticosteroids * infections * human immunodeficiency virus (hiv), hepatitis b virus (hbv) (not vaccination) and hepatitis c virus (hcv) positive 3. aortic stenosis * coronaropathies * pregnancy * other genetic diseases * neoplasms * collagenopathies * chemo/radiotherapy * prolonged use of corticosteroids * infections * human immunodeficiency virus (hiv), hepatitis b virus (hbv) (not vaccination) and hepatitis c virus (hcv) positive

Keywords: mirna lncrnas transcriptome heart failure aortic stenosis biomarkers
comparative efficacy study of titratable versus active mandibular advancement splint in sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: sleep apnea is a common disorder that occurs in 3-10 % of the adult population. this disorder disrupts the architecture and quality of sleep. continuous positive airway pressure (cpap) therapy is the standard treatment, but in some cases, it can not be used (patient refusal or intolerance). in these cases, treatment with mandibular advancement devices can bring an improvement in symptoms. therefore, this study aims to compare the effectiveness of titratable versus active mandibular advancement splints in standard care environment. this will be based on the global response, which includes the apnea-hypopnea index and compliance in severe apnea patients who refused or where intolerant to cpap. following their severe apnea diagnosis and the assessment on the feasibility of placing a mandibular advancement device, follow-up visits will be scheduled after 3 months of treatment involving clinical monitoring by a physician and a dentist.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * severe osa confirmed by polysomnography (psg) is: 30\> ahi\> 15 with severe daytime sleepiness - epworth ≥ 10 or ahi\> 30 * patient in failure or refusal of cpap treatment * agree to participate and sign the consent form research * speak and understand french without external assistance * be in good health (no neurological or psychiatric syndrome). * have a valid social security card (in france and portugal only) exclusion criteria: * contra-indicated dental/periodontal states for mandibular advancement splints, such as: 1) significant edentulism (less than 3 healthy teeth / quadrant), 2) generalized periodontitis or severe parodonthopathies, 3) severe disorders of the temporomandibular joint (tmj), 4) less than 5 mm of maximal mandibular protrusion * dental restorations in progress or planned in the next 6 months * psychiatric and neuromuscular disorders * untreated cardiovascular diseases and history of stroke or myocardial infarction * severe or morbid obesity (body mass index\> 35)

Keywords: obstructive sleep apnea mandibular advancement splint active mandibular advancement splint oral appliance
impact of an oligomeric diet in intestinal absorption and inflammatory markers in patients with crohn disease

Conditions: Crohn Disease; Absorption; Disorder, Protein; Absorption; Disorder; Absorption; Disorder, Fat; Absorption; Disorder, Carbohydrate; Malnutrition

Summary: this is a randomized, multicenter, translational, triple-blind, clinical trial in patients with crohn's disease, who will be prescribed an oral nutritional supplement to control symptoms in the acute phase and to recover in the remission phase.

multicentric, parallel, randomized, double blind and controlled clinical-nutritional study of 6 months of intervention and 3 study groups of treatment: experimental group (peptidic diet with a mix of probiotics); experimental group with placebo (peptidic diet with a placebo); and control group (control with a polymeric nutritional oral supplement with a placebo) to evaluate the effect on the nutritional status, inflammatory markers and the intestinal absorption

Eligibility criteria:
inclusion criteria: * unintentional weight loss of 5% in 6 months or a bmi less than 20kg/m2 or does not get the energy requirements with normal food. * willing to comply with the prescribed diet follow-up for cd. exclusion criteria: * having received antibiotics in the previous 3 months * having undergone intestinal resection surgery≥70-75% * refuse to participate in the study * comorbidity that allows to suspect survival \<1 year

Keywords: oligomeric diet peptidic diet probiotics oral nutritional supplements
phase 2 study of nx-1207 for the treatment of benign prostatic hyperplasia (bph) (enlarged prostate)

Conditions: Benign Prostatic Hyperplasia (BPH); Enlarged Prostate

Summary: this completed study evaluated the safety and efficacy of two dose levels of nx-1207 for the treatment of bph (benign prostatic hyperplasia) versus finasteride.

subjects randomized to nx-1207 were blinded as to the dose level of nx-1207 they received.

Eligibility criteria:
inclusion criteria: 1. documented history of bph for at least 1 year 2. aua si ≥ 15 3. prostate volume ≥ 30 ml ≤ 70 ml 4. qmax \< 15 ml/sec exclusion criteria: 1. history of illness or condition that may interfere with study or endanger subject 2. use of prescribed medications that may interfere with study or endanger subject 3. presence of a median lobe of the prostate 4. surgery or mist in the previous 12 months for treatment of bph 5. post-void residual urine volume \> 350 ml 6. psa ≥ 10 ng/ml; prostate cancer must be ruled out for psa ≥ 4 ng/ml

Keywords: benign prostatic hyperplasia bph enlarged prostate
a master protocol study of orforglipron (ly3502970) in participants with hypertension and obesity or overweight (attain-hypertension) gzl1

Conditions: Hypertension; Overweight or Obesity

Summary: gzl1 is an independent study conducted under the gzpl master protocol. gzl1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.


Eligibility criteria:
inclusion criteria: * refer to the gzpl master protocol for screening eligibility. exclusion criteria: * refer to the gzpl master protocol for screening eligibility.
itil-168 in advanced solid tumors

Conditions: Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer

Summary: delta-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of itil-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy. itil-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; tils).


Eligibility criteria:
key inclusion criteria: * histologically documented advanced (metastatic and/or unresectable) cervical cancer, hnscc, or nsclc. * cohort 1: participants with cervical cancer whose disease progressed during or after at least 1 prior line of chemotherapy. * cohort 2: participants with hnscc whose disease progressed during or after chemotherapy that must have included a platinum agent and previous cpi. * cohort 3: participants with nsclc whose disease progressed during or after 1 prior line of platinum-based chemotherapy and a cpi. participants with targetable mutations (e.g. egfr/alk) are required to have progressed on targeted therapy and platinum-based chemotherapy * medically suitable for surgical resection of tumor tissue * following tumor resection for til harvest, will have, at minimum, 1 remaining measurable lesion as identified by ct or mri per response evaluation criteria in solid tumors (recist) v1.1 * eastern cooperative oncology group (ecog) performance status 0 or 1 * adequate bone marrow and organ function key exclusion criteria: * history of another primary malignancy within the previous 3 years * neuroendocrine carcinoma, nasopharyngeal carcinoma, squamous cell carcinoma of the lip, or histopathology with neuroendocrine differentiation * previously received an allogeneic stem cell transplant or organ allograft * previously received til or engineered cell therapy (eg, car t-cell) * significant cardiac disease * stroke or transient ischemic attack within 12 months of enrollment * history of significant central nervous system (cns) disorder * symptomatic and/or untreated cns metastases * history of significant autoimmune disease within 2 years prior to enrollment * known history of severe, immediate hypersensitivity reaction attributed to cyclophosphamide, fludarabine, il-2, of cpi

Keywords: itil-168 cell therapy cervical cancer head and neck squamous-cell carcinoma (hnscc) non-small cell lung cancer (nsclc) autologous adoptive cell therapy cellular immunotherapy immuno-oncology tumor infiltrating lymphocytes til t-cell therapy il-2 pembrolizumab checkpoint inhibitor (cpi) pd-1 pathway inhibitors
protocol of virtual interactive memory-training program

Conditions: Mild Cognitive Impairment

Summary: this study sought to investigate the changes in objective memory performance (including immediate recall and delayed recall), subjective memory complaints and degree of depression in older adults with mild cognitive impairment after virtual interactive memory training (vimt).

this double-blind randomized controlled study has a 2-arm parallel group design. all subjects will be randomized by the block randomization, into intervention group (virtual interactive memory training, vimt), or active control group (passive information activities, pia). training sessions of the vimt group are 45 minutes/day, 3 days/week, for 12 weeks (36 sessions each). the training of pia group is the same as vimt group. we constructed a rigorous vimt program adhering to the consolidated standards of reporting trials (consort) reporting guidelines. the investigators expect to determine the improvement in memory function and degree of depression of older adults with mild cognitive impairment after using the vimt.

Eligibility criteria:
inclusion criteria: 1. participants must endorse at least two items from a list of frequent subjective memory complaints by patient and/or an informant 2. objective memory impairment on neuropsychological tests of memory 1.5 sd or more below age/education norms 3. clinical neurologic examination by the mini-mental state examination (mmse) score of 24 or higher, and cut-off score of 23/24 on the montreal cognitive assessment (moca) 4. no impairment in personal activities of daily living (p-adl) as determined by clinical interview with participant and family exclusion criteria: 1. the clinical diagnosis of dementia was based on the dsm-iv-tr 2. active in another cognitive or memory-related training in the past year 3. comorbid medical conditions that would predispose them to imminent functional decline or cognitive impairment 4. a diagnosis of major neurological or psychiatric illness history and/or behavioral problems that would sufficiently impair performance to make participation impossible 5. severe losses in vision, hearing, or communicative ability

Keywords: mild cognitive impairment memory training randomized controlled study
intraoperative analgesia based on ani

Conditions: Pain Monitoring; Pain Assessment; Opioid Consumption

Summary: osteoarthritis of the knee joint is common and total knee arthroplasty (tka) is performed in patients with advanced joint degeneration, no response to conservative treatments, severe pain and joint instability. severe pain levels between 4 and 8 in visual analog pain scale (vas) scores have been reported in the postoperative period. multimodal analgesia is considered to be the best option for pain control after total knee arthroplasty. multimodal analgesia is defined as the combined use of different analgesia techniques such as neuraxial analgesia, peripheral nerve blocks, patient-controlled analgesia and different analgesic drugs. for this purpose, peripheral nerve blocks are effectively applied as a component of multimodal analgesia. thus, side effects such as nausea, vomiting, pruritus and sedation that may occur due to opioid use are reduced. at the same time, in addition to providing effective analgesia, peripheral blocks contribute to early initiation of rehabilitation of the knee joint, early ambulation, reduction of pulmonary complications and early discharge from the hospital. recently, objective methods such as skin vasomotor reflex analysis, pupilometry, pulse plethysmographic signals and analgesia nociceptive index (ani) have been used to standardize the need for intraoperative analgesia in patients under general anesthesia. among these methods, ani is a non-invasive method that provides continuous measurement of parasympathetic tone, which is a part of the autonomic nervous system. electrodes are placed on the chest wall on both sides of the heart and the patient is monitored. the investigators aimed to compare the analgesia nociception index (ani) and the conventional method to determine perioperative analgesic needs in patients undergoing total knee arthroplasty under general anesthesia with femoral nerve block.


Eligibility criteria:
inclusion criteria: 1.18-75 years old, 2.asa i-ii-iii risk group 3.undergo knee operation under general anesthesia 4. patients with preoperative femoral nerve block 5. patients whose informed consent was read and consent was obtained from them and their guardian exclusion criteria: 1. those who do not want to participate in the study, 2. asa iv-v patients 3. those with central or autonomic nervous system disease

Keywords: analgesia nociception index opioid consumption pain management
asap: access to syringes at pharmacies for the prevention of bloodborne infections among people who inject drugs

Conditions: Skin and Soft Tissue Infections; Hiv; Hepatitis C; Bloodstream Infection

Summary: access to syringes at pharmacies (asap) is a refinement of an evidence-based, pharmacy intervention to increase pharmacy-based sales of syringes to pwid in order to reduce bloodborne illnesses among them.

the refinement integrates a motivational enhancement to reduce staff ambivalence about syringe sales to pwid (people who inject drugs), sampling improvements to assure that project pharmacies are likely serving pwid, and refinements to the intervention training content and delivery in three selected arizona project counties of mohave, maricopa and pima. our development and refinement of asap relies on: 1) interviews with pharmacy staff of 6 pharmacies (2 for each county) that will assess feasibility, acceptance and likely adoption of the initial draft of the asap intervention, and 2) interviews and surveys among pharmacy staff of 3 pharmacies (1 from each county). asap's adaptations and refinements will be guided by a highly iterative process between investigators and a community advisory board (cab). further, the consolidated framework for implementation research (cfir) will guide feasibility assessment with a focus on selected cfir elements across the domains of intervention characteristics, outer and inner setting, characteristics of individuals and process. the project will occur in two phases. the year 1 formative phase and is not a clinical trial will involve: 1) in-depth interviews with staff of 6 pharmacies to clarify intervention components, training and feasibility. findings will inform the year 2 iterative asap development and refinement phase and beta testing (clinical trial) between investigators and the cab; including extensive feedback from pharmacy staff of 3 pharmacies following an asap beta test. specific aims are: aim 1: to conduct the formative research among pharmacy staff required to develop and beta test the asap intervention materials (e.g., training manual, manual of operations, evaluation protocols). aim 2: to determine the feasibility of the asap intervention relative to impact on pharmacy syringe related sales and pharmacy interactions with pwid at time of syringe buy request.

Eligibility criteria:
inclusion criteria: * full time pharmacy staff member as a pharmacist or a pharmacy technician in an arizona pharmacy within the three study counties (pima, maricopa, mohave) exclusion criteria: * not a full time pharmacy staff member
association between live birth rate and serum progesterone during hormonal replacement therapy

Conditions: Ovarian Hyperstimulation Syndrome; Frozen-thawed Embryo Transfers

Summary: nowadays, frozen-thawed embryo transfers (fet) are expending. this practice avoids risk of ovarian hyperstimulation syndrome (ohss), as well as allowing better synchronization between endometrium and embryo, which is fundamental for pregnancy. there are several fet protocols, including hormonal replacement therapy cycle (hrt), which enable clinicians to adapt the day of embryo transfer. however, increase in spontaneous miscarriages was observed with this latter protocol compared to fresh embryo transfers and the other endometrial preparations (natural and stimulated), in relation with the lack of physiological corpus luteum. then, clinicians interrogate about measuring serum progesterone in order to adjust their treatment and/or transfer date. various studies have shown thresholds below and/or above which pregnancy or live birth rate were lowered. the main objective is to find a serum progesterone threshold on the day of embryo transfer above which live birth rate is increased. the secondary objectives are to analyze the factors associated with increased serum progesterone on the day of transfer, to analyze the miscarriage rate, and impact of change on luteal phase support on day 12.


Eligibility criteria:
inclusion criteria: * women between 18 and 43, * having frozen-thawed single embryo transfer of a day-5 blastocyst with hormonal replacement therapy, with measurement of serum progesterone on the day of transfer exclusion criteria: * frozen-thawed transfer of a day-2 or -3 or -6 embryo, * double embryo transfer, * other protocol than hrt, * patient without serum progesterone measurement on the day of transfer

Keywords: serum progesterone frozen-thawed embryo transfer live birth rate
preoperative oral heptaminol hydrochloride in preventing hypotension after spinal anesthesia

Conditions: Hypotension After Spinal Anesthesia

Summary: methodologies and approaches have been implemented with differing degrees of success to prevent neuraxial hypotension. currently utilized approaches to prevent hypotension during spinal anesthetic administration consist of physical precautions such as leg restraints and compression hosiery, as well as sympathomimetic medications through a competitive inhibition of noradrenaline uptake, heptaminol hydrochloride prevented orthostatic hypotension and increased the plasma concentration of noradrenaline. this inhibitory effect might account for a portion of the antihypotensive effect after thorough research of the literature, studies evaluating the role of preoperative oral heptaminol hydrochloride in preventing hypotension after spinal anesthesia in lower limb surgeries with tourniquets are lacking.


Eligibility criteria:
inclusion criteria: * age from 18 to 50 years old. * both sexes. * american society of anesthesiologists (asa) physical status i-ii. * undergoing elective orthopedic lower limb operations with a tourniquet or plastic surgeries under spinal anesthesia. exclusion criteria: * patient refusal. * history of hypertension, cardiovascular \[disorders of the heart and blood vessels and including coronary heart disease, rheumatic heart disease and other conditions\], and cerebrovascular diseases \[conditions that affect blood flow and the blood vessels in the brain. problems with blood flow may occur from blood vessel narrowing (stenosis), clot formation (thrombosis), artery blockage (embolism), or blood vessel rupture (hemorrhage)\]. * baseline sbp \>160 mm hg before administration of the drug. * any contraindications to spinal anesthesia such as coagulopathy, local skin infection, swelling, trauma, or deformity. * medical conditions, which release vasoconstrictors such as pheochromocytoma. * patients taking vasoconstrictors or uncorrected tachyarrhythmia. * history of drug allergy. * psychiatric, neuromuscular disorder, major systemic diseases. * pregnancy or lactating women. * inadequate effect of spinal anesthesia or supplemented with other types of anesthesia.
comparison between 2 treatment modalities of trigger finger: ultrasound-guided percutaneous release of a1 pulley by a needle knife versus ultrasound-guided corticosteroid injection in the treatment of trigger finger

Conditions: Trigger Finger

Summary: trigger finger is a common cause of hand disability and pain in the general population. it is a pathologic condition of the digital pulleys and flexor tendons. although the pathogenesis is incompletely clear and multifactorial, the most common cause of the trigger finger is the thickened flexor tendon and/or thickened first annular (a1) pulley located at the metacarpophalangeal joint. currently, ultrasound is considered an effective and valuable tool for assessing the trigger finger, providing static and dynamic evaluations of this condition and a comparison with the adjacent normal digits. recently, it has been reported that ultrasound-guided percutaneous a1 pulley precise release using a needle knife has received increasing attention in the clinical treatment of trigger fingers and achieved good results. to our knowledge, this is the first clinical study comparing the efficacy and safety of ultrasonic-guided percutaneous a1 pulley release with a needle knife and the ultrasonic-guided steroid injection in treating trigger fingers.


Eligibility criteria:
inclusion criteria: * idiopathic trigger finger * trigger finger at the level of a1 pulley * trigger finger of green's grades ii or iii exclusion criteria: * patients with secondary causes of trigger fingers like diabetes mellitus, rheumatoid arthritis, gout, hypothyroidism, amyloidosis, and sarcoidosis. * patients with a previous history of first annular pulley release or injection. * patients with trigger fingers of green's grade i and iv. * patients with trigger fingers at any level other than the a1 pulley.